Introduction
As the most frequent primary liver cancer, hepatocellular carcinoma (HCC) ranks as sixth most common cancer and the third leading cause of cancer-related death worldwide [1] . For the treatment of early-stage HCC, 3 types of treatments, including resection, liver transplantation and percutaneous ablation are potentially curative therapies [2] [3] [4] . Although cancer surveillance program increases the detection rate of early-stage HCC, the majority of HCC patients (exceeding 80%) are still diagnosed in intermediate or advanced stage, which excludes them from receiving curative treatments [2] [3] [4] [5] . According to Barcelona Clinic Liver Cancer (BCLC) staging system guideline, transarterial chemoemThis work by JBUON is licensed under a Creative Commons Attribution 4.0 International License. bolization (TACE) is the first-line treatment for HCC patients in intermediate stage, and TACE has recently been applied as bridge therapy to liver resection or transplantation in early-stage HCC as well [6] [7] [8] [9] [10] [11] [12] [13] .
TACE is a locoregional treatment that is utilized most commonly in unresectable HCC patients. The principle for conventional TACE (cTACE) is that carriers, such as lipiodol and ethiodized poppyseed oil (EPO), transport chemotherapeutic agents to targeted tumor and then the tumor supplying vessels are blocked by injecting vascular embolic agents, which would result in cytotoxic effect and ischemia [14, 15] . To date, a large number of studies illuminate that cTACE treatment has relatively high systemic release of chemotherapeutic agents, contributing to systemic side effects in HCC patients [16] [17] [18] . To avoid the shortcomings of cTACE, drug-eluting bead transarterial chemoembolization (DEB-TACE) has been developed, which uses microspheres loaded with chemotherapeutic agents instead as drug carriers, meanwhile, microspheres also serve as embolic agents. As a result, DEB-TA-CE is considered to minimize systemic exposure of chemotherapeutic agents and maximize the chemotherapeutic agent concentration in the tumor region in comparison to cTACE [17, [19] [20] [21] [22] [23] . So far, several drug-eluting bead (DEB) products are available for clinical use, including CalliSpheres® microspheres (CSM), DC Beads®, HepaSphere Microspheres® and superadsorbent microspheres (SAP) [24] . As the first DEB product in China, CSM possesses many good features like other DEBs, such as qualified biocompatibility, adequate physicochemical stability and advantages in drug loading and release [25, 26] . However, there are limited studies evaluating the clinical efficacy and safety of DEB-TACE with CSM in treating HCC patients. Therefore, the aim of this study was to compare the efficacy and safety between DEB-TACE with CSM and cTACE in HCC patients, and to explore their predictive factors for treatment response and survival profiles.
Methods

Patients
From 2016/2/1 to 2017/8/28, 89 HCC patients about to receive DEB-TACE or cTACE therapy in the Affiliated Tumor Hospital of Guangxi Medical University were consecutively recruited in this retrospective cohort study. The inclusion criteria were as follows: (1) primary HCC confirmed by clinical and pathological examinations according to the European Association for the Study of the Liver (EASL) criteria; (2) age above 18 years; (3) about to receive DEB-TACE or cTACE treatment; (4) life expectancy was more than 12 months; (5) able to be followed up regularly. Patients were excluded if they had the following conditions: (1) contraindications to TACE or anthracyclines; (2) undergoing thrombolysis or anticoagulant therapy; (3) history of hematological malignancies; (4) renal failure, congestive heart failure, recent myocardial infarction or uncontrolled arrhythmias; (5) active infection (hepatitis infection could be accepted); (6) during gestation or lactation period or planned to be pregnant. All patients receiving DEB-TACE or cTACE treatment were assigned to DEB-TACE group (n=42) or cTACE group (n=47). This study protocol was approved by Ethics Committee of the Affiliated Tumor Hospital of Guangxi Medical University, and the study was performed according to the Declaration of Helsinki. All patients provided written informed consents before enrollment.
Characteristics of patients at baseline (M0)
Comprehensive baseline characteristics of patients were collected after clinicopathological examinations and biochemical tests, which included demographic features, medical history and clinical characteristics, biochemical indexes and previous treatments, and the details were as follows: (1) demographic features: age, gender; (2) medical history and clinical characteristics: history of hepatitis B (HB), history of hepatitis C (HC), history of drink, history of cirrhosis, tumor location, tumor distribution, largest nodule size, portal vein invasion, hepatic vein invasion, Eastern Cooperative Oncology Group (ECOG) performance status, Child-Pugh stage and Barcelona Clinic Liver Cancer (BCLC) stage; (3) blood routine indexes: white blood cell (WBC), red blood cell (RBC), absolute neutrophil count (ANC), haemoglobin (Hb) and platelet (PLT); (4) liver function indexes: albumin (ALB), total protein (TP), total bilirubin (TBIL), total bile acid (TBA), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP); (5) renal function indexes: blood creatinine (BCr) and blood urea nitrogen (BUN); (6) tumor markers: alpha fetoprotein (AFP), carcinoembryonic antigen (CEA) and carbohydrate antigen19.9 (CA19.9); (7) previous treatments: cTACE, surgery, systemic chemotherapy, radiofrequency ablation and targeted therapy.
Procedures
1. Pretreatments: before DEB-TACE or cTACE treatment, antiemetic treatment using tropisetron (Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Shandong Province, China), analgesic treatment using dezocine (Yangtze River Pharmaceutical Group, Jiangsu Province, China) and anti-infection treatments were given to patients.
2. Drug loading process of DEB-TACE: the CSM (Jiangsu Hengrui Medicine Co., Ltd., Jiangsu Province, China) with diameters of 100-300 μm was used as carrier for chemotherapeutics and embolization agents in the DEB-TACE procedures. The CSM was loaded with pirarubicin (60-80 mg) (Shenzhen Main Luck Pharmaceuticals Inc., Guangdong Province, China) using the following methods: the CSM and normal saline were extracted by a 20 mL syringe and were erectly placed at room temperature (RT) for 1-2 min until the CSM was totally precipitated, then the chemoembolization reagent which was dissolved into a 20 mg/mL solution was mixed with the CSM, and the mixture was shaken gently every 5 min within 15 min until the CSM was totally loaded with the chemoembolization reagent. Subsequently, the high concentration contrast agent was added into the mixture as 1:1, 1:1.1 or 1:1.2 ratio, and then the mixture was kept still for 5 min for further use. 3. DEB-TACE operation: all DEB-TACE procedures were performed in the digital subtraction angiography (DSA) room and before DEB-TACE, the targeted tumor was assessed by triphasic computerized tomography (CT) or magnetic resonance imaging (MRI) according to the Milan criteria [27, 28] . DEB-TACE procedures were performed as follows: the hepatic angiography was performed to detect the tumor supplying vessels using segment or subsegment super selective catheterization; right after the tumor supplying vessels were selected, the femoral artery was punctured using the Seldinger technique, and the microcatheter with a diameter of 2.7F (Merit Maestro, Merit Medical System, Inc., Utah, USA) was used for catheterization. Afterwards, the CSMs were injected through the microcatheter by pulse injection, and the embolization ended as soon as the flow of contrast agent stagnated. After the embolization, the microcatheter was pulled out, and the wound was pressed for hemostasis and bandaged. In addition, for the patients with massive HCC, DEB-TACE was performed multiple times. 4. cTACE operation: cTACE procedures were also performed in the DSA room. Firstly, the hepatic angiography was performed to detect the tumor supplying vessel using the same methods as the ones used in DEB-TACE procedures. Secondly, once the tumor supplying vessel was identified, the percutaneous femoral artery was punctured using the Seldinger technique. Thirdly, a 2.7F microcatheter was subsequently used for catheterization, and the chemotherapy drug solution (pirarubicin 60-80 mg, 20 mg/mL), normal lipiodol or ethiodized poppyseed oil (EPO) (Jiangsu Hengrui Medicine Co., Ltd., Jiangsu Province, China) as drug carriers and blank CSMs (Jiangsu Hengrui Medicine Co., Ltd., Jiangsu Province, China) with diameters of 100-300μm, 300-500μm or 500-700μm as embolization agents were injected into the tumor supplying vessel. Finally, the embolization was stopped when the flow of infusion became stagnated. In addition, the angiography was performed for another time to ensure the normal lipiodol, EPO or blank CSMs were deposited and to detect if there was incomplete embolization. 5. Posttreatments: all patients were told to lie on one side and extend the punctured leg for 6-12 h after embolization. Patients with postoperative nausea and vomiting were treated by tropisetron (IV), and analgesic treatment was given to patients using pethidine, dexamethasone or lidocaine. In addition, the liver protection treatments using Magnesium isoglycyrrhizinate, glutathione and polyene phosphatidyl choline were also given to patients.
Assessments after treatment
Clinical examinations such as enhanced CT or MRI scanning were performed at month 1 (M1), M3 or M6 after treatment to assess the treatment response, and liver function indexes including ALT, AST, ALP, TBIL, ALB, TP and TBA were measured at M1 after treatment to evaluate the biochemical toxicity. In addition, adverse events which occurred during the operation and hospitalization were recorded. Pain grade was evaluated using Numeric rating scale (NRS), which was a 10-point numeric scale, with 0 representing "no pain", 1-3 "mild pain", 4-6 "moderate pain", 7-9 "severe pain" and 10 "unbearable pain".
Definitions
According to the modified Response Evaluation Criteria in Solid Tumors (mRECIST), the response criteria included complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD), and the detailed definitions were as follows: (1) CR: no existence of arterial enhancement of target tumors; (2) PR: at least a 30% decrease in the sum of the diameters of target tumors (contrast enhancing); (3) SD: any cases that did not qualify for either PR or PD; (4) PD: the increase in the sum of diameters of target tumors (with arterial enhancement) ≥20% or occurrence of new tumors. In addition, objective response rate (ORR) was defined as the percentage of patients who achieved CR or PR, and disease control rate (DCR) was defined as the percentage of patients who achieved CR, PR or SD.
Survival assessment
Progression free survival (PFS) and overall survival (OS) were calculated for survival assessment, which were defined as follows: (1) PFS: the duration from the time of treatment to the time of disease progression; (2) OS: the duration from the time of treatment to the time of patient's death from any cause.
Follow up
Patients were followed up by phone calls or hospitalization, the median follow-up duration was 9.9 months (range 1.8-24.5), and the last follow-up date was 2018/4/21. Finally, patients with at least one response assessment after DEB-TACE or cTACE treatment were included in the final analysis, while patients were excluded from final analysis if they (1) switched to cTACE treatment due to lack of efficacy within the duration of treatment response assessment of DEB-TACE therapy, (2) received DEB-TACE treatment because of lacking efficacy within the duration of treatment response assessment of cTACE therapy, (3) lost to follow-up without any response assessment, (4) withdrew the informed consents. Table 1 . Patient baseline characteristics between two groups was determined by Chi-square test; normally distributed continuous variables were presented as mean value ± standard deviation, and the comparison between two groups was determined by t-test; skewed distributed continuous variables were described as median (25 th -75 th quantiles), and the comparison between two groups was determined by Wilcoxon rank sum test. Factors affecting ORR were determined by univariate and multivariate logistic regression analysis, and the multivariate logistic regression analysis was performed using the Forward Stepwise (Conditional) method. PFS and OS were analyzed using the Kaplan-Meier method and Log-rank test. Univariate Cox's proportional hazards regression analyses were performed to determine the prognostic factors of PFS and OS, and multivariate Cox's proportional hazards regression analyses were further performed to determine the independent prognostic factors of PFS and OS with the use of Forward Stepwise (Conditional LR) method. P value <0.05 was considered statistically significant.
Statistics
Results
Baseline characteristics
The mean age was 52.9 ± 11.8 years in the DEB-TACE group (n=42) and 51.9 ± 13.1 years in the cTACE group (n=47) (p=0.703), and there were 37 males and 5 females in the DEB-TACE group, and 44 males as well as 3 females in the cTACE group (p=0.363). As for tumor features, DEB-TACE group exhibited more patients with unifocal tumor distribution (p=0.034), larger mean largest nodule size (p=0.005), more patients in B/C stage (p=0.032) compared to cTACE group, while no difference of Figure 1 . Difference of CR rate, ORR and DCR between DEB-TACE group and cTACE group at M1, M3 and M6. Higher CR rate (A) and ORR (B) at M1/M3 were present in DEB-TACE group compared to cTACE group and no difference was discovered at M6, while there was no difference of DCR (C) at M1/M3/M6 between the two groups. Chi-square test was used to compare the difference of CR rate, ORR and DCR between the two groups. P value <0.05 was considered significant. CR: complete response; ORR: objective response rate; DCR: disease control rate; DEB-TACE: drug-eluting bead transarterial chemoembolization; cTACE: transarterial chemoembolization; M: month.
ECOG PS (p=0.168) and BCLC stage (p=0.696) was noted between the two groups. As for liver function, higher TBIL level (p=0.003) and more patient with TBIL ≥1ULN (p=0.002) were present in DEB-TACE group compared to cTACE group. Concerning tumor markers, the CEA level was decreased in DEB-TACE group compared to cTACE group (p=0.022). Additionally, less patients were operated in the DEB-TACE group compared to cTACE group (p=0.030). Other detailed baseline characteristics were shown in Table 1 .
Comparison of treatment response rate between DEB-TACE group and cTACE group
Compared to cTACE group, CR (M1, p=0.026; M3, p=0.029) and ORR (M1, p=0.021; M3, p=0.026) were increased in the DEB-TACE group at M1/M3, whereas no difference in CR (p=0.422) or ORR at M6 (p=0.350) was seen between the two groups ( Figure 1A-1B) . In addition, there was no difference of DCR at M1 (p=0.179), M3 (p=0.727) or M6 (p=0.368) between the two groups ( Figure 1C ).
Factors affecting ORR at M1, M3 and M6
Univariate logistic regression analysis revealed that at M1, DEB-TACE was associated with higher ORR with OR 3.477, 95% CI 1.172-10.319 (p=0.025), while bilobar tumor location (p=0.017, OR 0.284, 95% CI 0.101-0.798) and multifocal disease (p=0.026, OR 0.312, 95% CI 0.111-0.872) were correlated with lower ORR ( Table 4) .
Comparison of PFS/OS between DEB-TACE group and cTACE group
The mean PFS was 12.7 months (95% CI, 10.1-15.4) in DEB-TACE group and 12.2 months (95% CI, 10.0-14.3) in cTACE group, and no difference of PFS was discovered between the two groups (p=0.516) (Figure 2A) . As for OS, the mean OS was 15.0 months (95% CI, 11.9-18.2) in the DEB-TACE group and 13.1 months (95% CI, 10.5-15.7) in the cTACE group (p=0.976) ( Figure 2B ). OS (B) was noted between DEB-TACE group and cTACE group. Kaplan-Meier curves and log-rank test were used to compare DFS and OS between DEB-TACE group and cTACE group. P value <0.05 was considered significant. DEB-TACE: drug-eluting bead transarterial chemoembolization; cTACE: transarterial chemoembolization. 
Factors affecting survival
Comparison of liver function between DEB-TACE group and cTACE group
At M1 after treatment, decreased ALB level (p=0.007), increased ALP level (p=0.001) and larger proportion of patients with ALP≥1ULN (p=0.004) were observed in DEB-TACE group compared to cTACE group (Table 7) . However, these differences were associated with numerically lower ALB level, higher ALP level and more patients with ALP≥1ULN in DEB-TACE group at M0. According to these findings, it is difficult to evaluate liver injury between the two groups. In order to further assess the effect of DEB-TACE and cTACE on liver injury, we further compared the changes (M1-M0) of liver function indexes, which disclosed that there was no difference of all liver function indexes changes between two groups (Figure 3) .
Comparison of adverse events between DEB-TACE group and cTACE group during treatment and hospitalization
During treatment, pain was higher in the DEB-TACE group compared to cTACE group (p<0.001). .05 was considered significant, and the significant results were shown in boldface. "-" indicated that the data were unable to compare due to lack of events. DEB-TACE: drug-eluting bead transarterial chemoembolization; cTACE: conventional transarterial chemoembolization; ULN: upper limit of normal; ALB: albumin; TP: total protein; TBIL: total bilirubin; TBA: total bile acid; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase. Significant results are shown in boldface. Table 7 . Liver function testing at 1 month (M1) post-treatment During hospitalization, pain (p=0.017) and fever (p=0.013) were also more intense in the DEB-TACE group compared to cTACE group (Table 8) .
Discussion
In the present study, we observed the following: 1) higher CR/ORR and similar DFS/OS were observed in DEB-TACE group compared with cTACE group; 2) multifocal disease, ALT ≥1ULN and ALP ≥1ULN predicted lower ORR independently, and bilobar tumor location as well as abnormal CA19.9 level were independent predictive factors for unfavorable PFS; 3) liver function damage of patients did not differ between DEB-TACE group and cTACE group; 4) DEB-TACE group exhibited more frequent pain during treatment, and more frequent pain/ fever during hospitalization compared to cTACE group.
The treatment efficacy of DEB-TACE with various DEBs versus cTACE in HCC patients has been investigated in numerous studies, whereas no consensus has been achieved [29] [30] [31] [32] [33] [34] [35] [36] . A cohort study disclosed that at M3 post operation, the CR rate (55 vs. 23.1%) and ORR (81.6 vs. 49.4%) were higher in patients treated with DEB-TACE using DC beads® compared to cTACE [29] . Another clinical study of DEB-TACE with SAP versus cTACE revealed no difference of ORR (50 vs. 62%) between two groups [37] . For CSM as drug carrier, one published study compared the efficacy between DEB-TACE with CSM and cTACE, which disclosed that CR (M3: 25.0 vs. 3.3%; M6: 20.8 vs. 0%) and ORR (M3: 83.3 vs. 43.3%; M6: 62.5 vs. 30.0%) at M3/M6 were increased compared to cTACE group [38] . With respect to survival, multiple studies illuminate that the DFS and OS in HCC patients receiving DEB-TACE were not inferior to that in patients receiving cTACE [31] [32] [33] [34] . For instance, a retrospective study 45 .0%) at M1/M3 compared to cTACE group, whereas there was no difference of PFS and OS between the two groups. The higher short-term CR and ORR in patients receiving DEB-TACE treatment with CSM may be due to the fact that CSM could achieve continuously high concentration of chemotherapeutic agents at least 1 month and over 200μm diffusing distance, which led to higher tumor tissue concentration of pirarubicin compared to cTACE, thereby DEB-TACE group showed better treatment response [38, 39] . In addition, DEB-TACE group exhibited comparable PFS and OS, which might be attributed to relatively short follow-up time and survival profiles affected by various factors, such as comorbidities and patients receiving other therapies. With regard to the predictive factors for treatment response and survival, a growing number of studies have disclosed 3 major factors including tumor features, tumor markers and liver function index levels [32, 33, [40] [41] [42] . Concerning treatment response, one study in HCC patients receiving DEB-TACE with DC beads® displayed that tumor location in the segments 1 and 4 were independent factors for predicting decreased CR, whereas tumor size <5 cm independently predicted increased CR [41] . Another study conducted in HCC patients treated with DEB-TACE using CSM revealed that number of nodules > 3, elevated BCLC stage and previous cTACE were associated with worse ORR, while none of these three factors independently predicted ORR [42] . With respect to survival, a retrospective, single-center study revealed that increased Child-Pugh stage and more severe portal invasion independently predicted poorer OS in HCC patients receiving cTACE or DEB-TACE with DC beads® [33] . A randomized controlled trial discovered that advanced Eastern Cooperative Oncology Group performance status (ECOG PS), elevated ALB and multiple tumors were independent factors for predicting shorter OS in HCC patients receiving cTACE or DEB-TACE with DC beads® [32] . In addition, hepatitis B, presence of ascites, advanced ECOG PS, higher Okuda stage and AFP level (>400) were independent predictors of worse OS in advanced HCC patients receiving DEB-TACE with DC beads® [40] . In this study, we disclosed that multifocal disease, ALT ≥1ULN and ALP ≥1ULN were independent predicting factors for poorer treatment response, and bilobar tumor location as well as abnormal CA19.9 level independently predicted shorter PFS in HCC patients treated with DEB-TACE using CSM or cTACE. These findings in our study could result from that: 1) multifocal disease and tumor location-bilobar were associated with more severe disease condition of HCC patients, suggesting increasing chances of blood vessels invasion and metastasis, which limited treatment efficacy of DEB-TACE or TACE in these patients, thereby leading to unfavorable treatment response or survival; 2) abnormal ALT and ALP levels indicated worse liver function, contributing to less tolerability to DEB-TACE or cTACE procedure and greater procedure-related damage to liver, thus these patients presented with poorer prognosis; 3) as an important tumor marker, increased CA19.9 level was associated with elevated grade of liver tumor malignancy, resulting in less response to DEB-TACE or cTACE treatment, hence treatment efficacy might shrink [43, 44] .
Damaged liver function is one of the major safety concerns in HCC patients treated by TACE, and a large number of studies uncover that DEB-TACE is similar to cTACE regarding liver damage [29] [30] [31] [32] [33] 35, 36, [45] [46] [47] . For example, no difference of liver function indexes changes (including ALP, ALT, TBIL, AST, ALB) in HCC patients was observed between DEB-TACE with DC beads® and cTACE [48] . Another study compared liver function indexes (including ALB, TP, ALT, AST and TBIL) before and after treatment between DEB-TACE with CSM and cTACE, which revealed that no differences in liver function indexes between the two groups before treatment, while at M1 after treatment, there were lower levels of AST, ALT and TBIL in patients receiving DEB-TACE with CSM compared to cTACE [38] . Partially in accordance with these previous studies, we also discovered no difference of liver function indexes changes (M1-M0) (including ALB, TP, TBIL, TBA, ALT, AST, ALP) between DEB-TACE with CSM and cTACE. Liver damage of HCC patients receiving TACE treatments is a result of heterogeneous causes, including chemotherapeutic agent toxicity and procedure-related damage to liver, as well as tumor ischemic necrosis. Whatever the reason may be, we found that in our study DEB-TACE with CSM and cTACE had parallel effects on liver function.
A majority of studies disclose no difference of procedure-related adverse events (including abdominal pain, transient fever, nausea and vomiting) between DEB-TACE and cTACE in HCC patients [29, 31, 32, 35, 36, 40, [46] [47] [48] . For example, a shortterm study concluded that HCC patients treated by DEB-TACE with DC beads® showed similar adverse events rates compared to patients treated with cTA-CE [48] . And a randomized controlled trial (RCT) revealed that the incidence and severity of adverse events (including post-procedural fever, fatigue, nausea/vomiting, haematoma, cholecystitis, spleen infarction, infection, liver abscess) did not differ between DEB-TACE with DC beads® and cTACE, while post-procedural pain was less frequent and severe in HCC patients receiving DEB-TACE with DC beads® [32] . In this study, compared to cTACE group, patients treated with DEB-TACE using CSM exhibited higher rates of pain during treatment and increased rates of pain/fever during hospitalization. Worse baseline tumor features in DEB-TACE group might require larger dose of pirarubicin, and the high chemotherapeutic dose along with the better treatment response in DEB-TACE group that caused more necrosis of the tumor together increased the incidence of pain and fever occurring during treatment and hospitalization in DEB-TACE group [49] .
Limitations existed in this study. Firstly, the number of enrolled patients was relatively small, leading to less statistical power. Secondly, as a retrospective study, there might be some confounding factors, however, we conducted multivariate regression analyses to diminish the confounding effect. Thirdly, the follow-up duration for assessing treatment response and survival was relatively short, thus the long-term efficacy of DEB-TACE with CSM compared to cTACE in HCC were not evaluated.
In summary, the short-term CR and ORR of DEB-TACE treatment with CSM are better, while OS, DFS and safety were equivalent compared to cTACE in treating HCC patients.
